LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway

References

• Pan F, Ruan Z, Li J, Pang X, Zhang Y, Zou L, Liang H. Radiotherapy combined docetaxel and oxaliplatin chemotherapy is effective in patients with locally advanced nasopharyngeal carcinoma. Med Oncol. 2015;32(11):252. doi:10.1007/s12032-015-0698-4. PMID:26471179.
   PubMed Web of Science ®Google Scholar
• Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, Slevin NJ, Homer JJ, Lee LW. Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Clin Oncol (R Coll Radiol). 2013;25(3):171–7. doi:10.1016/j.clon.2012.10.006. PMID:23337060.
   PubMed Web of Science ®Google Scholar
• Bergamini A, Pisano C, Di Napoli M, Arenare L, Della Pepa C, Tambaro R, Facchini G, Gargiulo P, Rossetti S, Mangili G, et al. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. Gynecol Oncol. 2017;144(1):72–76. doi:10.1016/j.ygyno.2016.10.023. PMID:28094039.
   PubMed Web of Science ®Google Scholar
• Johnsson P, Morris KV. Expanding the functional role of long noncoding RNAs. Cell Res. 2014;24(11):1284–5. doi:10.1038/cr.2014.104. PMID:25104732.
   PubMed Web of Science ®Google Scholar
• Bergmann JH, Spector DL. Long non-coding RNAs: modulators of nuclear structure and function. Curr Opin Cell Biol. 2014;26:10–18. doi:10.1016/j.ceb.2013.08.005. PMID:24529241.
   PubMed Web of Science ®Google Scholar
• Hu X, Jiang H, Jiang X. Downregulation of lncRNA ANRIL inhibits proliferation, induces apoptosis, and enhances radiosensitivity in nasopharyngeal carcinoma cells through regulating miR-125a. Cancer Biol Ther. 2017;18(5):331–8. doi:10.1080/15384047.2017.1310348. PMID:28402230.
   PubMed Web of Science ®Google Scholar
• Deng H, Zhang J, Shi J, Guo Z, He C, Ding L, Tang JH, Hou Y. Role of long non-coding RNA in tumor drug resistance. Tumour Biol. 2016;37(9):11623–31. doi:10.1007/s13277-016-5125-8. PMID:27380056.
   PubMedGoogle Scholar
• Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat commun. 2014;5:5383. doi:10.1038/ncomms6383. PMID:25415230.
   PubMed Web of Science ®Google Scholar
• Li Y, Li Y, Chen W, He F, Tan Z, Zheng J, Wang W, Zhao Q, Li J. NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancer. Oncotarget. 2015;6(29):27641–50. doi:10.18632/oncotarget.4737. PMID:26314847.
   PubMedGoogle Scholar
• Almnaseer ZA, Mourtada-Maarabouni M. NEAT1, a long non-coding RNA, controls cell survival and is up-regulated in breast cancer. Eur J Cancer. 2016;61:S75–6. doi:10.1016/S0959-8049(16)61263-7..
   Google Scholar
• Fang L, Sun J, Pan Z, Song Y, Zhong L, Zhang Y, Liu Y, Zheng X, Huang P. Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VCP-IkappaB. Am J Physiol Gastrointest Liver Physiol. 2017;313(2):G150–g156. doi:10.1152/ajpgi.00426.2016. PMID:28526689.
   PubMed Web of Science ®Google Scholar
• Zeng C, Xu Y, Xu L, Yu X, Cheng J, Yang L, Chen S, Li Y. Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells. BMC Cancer. 2014;14:693. doi:10.1186/1471-2407-14-693. PMID:25245097.
   PubMed Web of Science ®Google Scholar
• Liu F, Chen N, Gong Y, Xiao R, Wang W, Pan Z. The long non-coding RNA NEAT1 enhances epithelial-to-mesenchymal transition and chemoresistance via the miR-34a/c-Met axis in renal cell carcinoma. Oncotarget. 2017;8(38):62927–38. doi:10.18632/oncotarget.17757. PMID:28968960.
   PubMedGoogle Scholar
• Lu Y, Li T, Wei G, Liu L, Chen Q, Xu L, Zhang K, Zeng D, Liao R. The long non-coding RNA NEAT1 regulates epithelial to mesenchymal transition and radioresistance in through miR-204/ZEB1 axis in nasopharyngeal carcinoma. Tumour Biol. 2016;37(9):11733–41. doi:10.1007/s13277-015-4773-4. PMID:27020592.
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33. doi:10.1016/j.cell.2009.01.002. PMID:19167326.
   PubMed Web of Science ®Google Scholar
• Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007;67(20):9762–70. doi:10.1158/0008-5472.CAN-07-2462. PMID:17942906.
   PubMed Web of Science ®Google Scholar
• Xu C, Sun X, Qin S, Wang H, Zheng Z, Xu S, Luo G, Liu P, Liu J, Du N, et al. Let-7a regulates mammosphere formation capacity through Ras/NF-kappaB and Ras/MAPK/ERK pathway in breast cancer stem cells. Cell Cycle. 2015;14(11):1686–97. doi:10.1080/15384101.2015.1030547. PMID:25955298.
   PubMed Web of Science ®Google Scholar
• Liu TP, Huang CC, Yeh KT, Ke TW, Wei PL, Yang JR, Cheng YW. Down-regulation of let-7a-5p predicts lymph node metastasis and prognosis in colorectal cancer: implications for chemotherapy. Surg Oncol. 2016;25(4):429–34. doi:10.1016/j.suronc.2016.05.016. PMID:27262492.
   PubMed Web of Science ®Google Scholar
• Wong TS, Man OY, Tsang CM, Tsao SW, Tsang RK, Chan JY, Ho WK, Wei WI, To VS. MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. J Cancer Res Clin Oncol. 2011;137(3):415–22. doi:10.1007/s00432-010-0898-4. PMID:20440510.
   PubMed Web of Science ®Google Scholar
• Yu CC, Chen YW, Chiou GY, Tsai LL, Huang PI, Chang CY, Tseng LM, Chiou SH, Yen SH, Chou MY, et al. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol. 2011;47(3):202–10. doi:10.1016/j.oraloncology.2010.12.001. PMID:21292542.
   PubMed Web of Science ®Google Scholar
• Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest. 2013;123(6):2395–407. doi:10.1172/JCI66553. PMID:23676502.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635–47. doi:10.1016/j.cell.2005.01.014. PMID:15766527.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang W, Hao S. LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis. Cell Cycle. 2017;16(8):795–801. doi:10.1080/15384101.2017.1301334. PMID:28358263.
   PubMed Web of Science ®Google Scholar
• Ren S, Li G, Liu C, Cai T, Su Z, Wei M, She L, Tian Y, Qiu Y, Zhang X, et al. Next generation deep sequencing identified a novel lncRNA n375709 associated with paclitaxel resistance in nasopharyngeal carcinoma. Oncol Rep. 2016;36(4):1861–7. doi:10.3892/or.2016.4981. PMID:27498905.
   PubMed Web of Science ®Google Scholar
• Li H, Zhang Y, Zhang Y, Bai X, Peng Y, He P. Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker. Tumour Biol. 2014;35(6):5771–6. doi:10.1007/s13277-014-1766-7. PMID:24584698.
   PubMedGoogle Scholar
• Ren J, Chen QC, Jin F, Wu HZ, He M, Zhao L, Yu ZJ, Yao WF, Mi XY, Wang EH, et al. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer. Int J Clin Exp Pathol. 2014;7(9):5595–608. PMID:25337201.
   PubMed Web of Science ®Google Scholar
• Liu S, Dong Q, Wang E. Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer. Tumour Biol. 2012;33(5):1485–91. doi:10.1007/s13277-012-0399-y. PMID:22528946.
   PubMedGoogle Scholar
• Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, Wang TL, Shih IeM. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res. 2009;69(4):1407–15. doi:10.1158/0008-5472.CAN-08-3602. PMID:19190325.
   PubMed Web of Science ®Google Scholar
• Yang YI, Ahn JH, Lee KT, Shih Ie M, Choi JH. RSF1 is a positive regulator of NF-kappaB-induced gene expression required for ovarian cancer chemoresistance. Cancer Res. 2014;74(8):2258–69. doi:10.1158/0008-5472.CAN-13-2459. PMID:24566868.
   PubMed Web of Science ®Google Scholar
• Tai HC, Huang HY, Lee SW, Lin CY, Sheu MJ, Chang SL, Wu LC, Shiue YL, Wu WR, Lin CM, et al. Associations of Rsf-1 overexpression with poor therapeutic response and worse survival in patients with nasopharyngeal carcinoma. J Clin Pathol. 2012;65(3):248–53. doi:10.1136/jclinpath-2011-200413. PMID:22081787.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li G, Liu C, Tang Y, Zhang S. RSF1 regulates the proliferation and paclitaxel resistance via modulating NF-kappaB signaling pathway in nasopharyngeal carcinoma. J Cancer. 2017;8(3):354–62. doi:10.7150/jca.16720. PMID:28261335.
   PubMed Web of Science ®Google Scholar
• Dhawan NS, Scopton AP, Dar AC. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Nature. 2016;537(7618):112–6. doi:10.1038/nature19327. PMID:27556948.
   PubMed Web of Science ®Google Scholar
• Delire B, Starkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest. 2015;45(6):609–23. doi:10.1111/eci.12441. PMID:25832714.
   PubMed Web of Science ®Google Scholar
• Hrustanovic G, Bivona TG. RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer. Mol Cell Oncol. 2016;3(2):e1091061. doi:10.1080/23723556.2015.1091061. PMID:27308613.
   PubMed Web of Science ®Google Scholar
• Zhao X, Ponomaryov T, Ornell KJ, Zhou P, Dabral SK, Pak E, Li W, Atwood SX, Whitson RJ, Chang AL, et al. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. Cancer Res. 2015;75(17):3623–35. doi:10.1158/0008-5472.CAN-14-2999-T. PMID:26130651.
   PubMed Web of Science ®Google Scholar